Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 9Phase 1 6Phase 1/2 3Phase NA 2Phase 2/3 2Phase 4 1

Status

Terminated 3Completed 2Suspended 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Gynecologic 1CNS 1Breast 1

Conditions

Neoplasms 2Ovarian Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × taxane × Clear all
NCT06332508 2026-03-13

Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)

National University Hospital, Singapore

Phase 1 Completed
14 enrolled
Breast

Breast Neoplasms

NCT04711161 2024-01-23

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Green3Bio, Inc.

Phase 1 Suspended
73 enrolled
Gynecologic

Ovarian Neoplasms

NCT02187822 2021-02-04

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
15 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT00970580 2013-09-16

A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Biogen

Phase 1 Completed
18 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00326131 2010-03-02

A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1 Terminated
6 enrolled
Tumor-Agnostic

Neoplasms

NCT00332748 2010-03-02

A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1 Terminated
36 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡